For the Inventor, By the Inventor

Enter assignee name

Newark, CA, United States of America

Protagonist Therapeutics, Inc.

USPTO Granted Patents = 32

EPO Patents = 8

Trademarks = 1

Forward Citations = 398

Loading Chart...

Loading Chart...

44 inventors (with patents filed for the assignee):

Ashok Bhandari (26 out of 28 patents)

Brian Troy Frederick (25 out of 27 patents)

Gregory Thomas Bourne (18 out of 20 patents)

4. Dinesh Vinoobhai Patel (16 out of 57 patents)

5. David Y Liu (15 out of 108 patents)

6. Larry C Mattheakis (10 out of 19 patents)

7. Jie Zhang (10 out of 11 patents)

8. Mark Leslie Smythe (9 out of 14 patents)

9. Genet Zemede (8 out of 14 patents)

10. Xiaoli Cheng (7 out of 8 patents)

11. Simone Vink (6 out of 6 patents)

12. Praveen Madala (6 out of 6 patents)

13. Anne Pernille Tofteng Shelton (6 out of 6 patents)

14. Jacob Ulrik Fog (6 out of 11 patents)

15. Chengzao Sun (3 out of 3 patents)

32 patents: Sort by Forward Citations

1. 12478617 - Lipidated peptide inhibitors of interleukin-23 receptor (2025-11-25),

2. 12269856 - Hepcidin analogues and uses thereof (2025-04-08),

3. 12234300 - Conjugated hepcidin mimetics (2025-02-25),

4. 12018057 - Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases (2024-06-25),

5. 11939361 - Compositions of peptide inhibitors of Interleukin-23 receptor (2024-03-26),

6. 11884748 - Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases (2024-01-30),

7. 11845808 - Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases (2023-12-19),

8. 11840581 - α4β7 thioether peptide dimer antagonists (2023-12-12),

9. 11807674 - Hepcidin analogues and uses thereof (2023-11-07),

10. 11753443 - Conjugated hepcidin mimetics (2023-09-12),

11. 11472842 - Analogues of hepcidin mimetics with improved in vivo half lives (2022-10-18),

12. 11111272 - α4α7 peptide monomer and dimer antagonists (2021-09-07),

13. 11041000 - Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases (2021-06-22),

14. 10941183 - Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases (2021-03-09),

15. 10729676 - Opioid agonist peptides and uses thereof (2020-08-04),

Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing peptide-based therapeutics. They utilize their proprietary technology platform to create oral and injectable peptides to address unmet medical needs. With a focus on gastrointestinal and inflammatory diseases, their innovative approach aims to provide effective and safer treatments for patients.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

32 Patents

#22 in Newark, CA

#2,459 in California

#10,247 in US

#20,095 in the World

Newark, CA, United States of America

Protagonist Therapeutics, Inc.

Forward Citations = 398

44 inventors:

Ashok Bhandari (26 out of 28 patents)

Brian Troy Frederick (25 out of 27 patents)

Gregory Thomas Bourne (18 out of 20 patents)

4. Dinesh Vinoobhai Patel (16 out of 57 patents)

5. David Y Liu (15 out of 108 patents)

Please report any incorrect information to support@idiyas.com

Loading…